Silver Book Fact

A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • According to the National Center for Health Statistics, if all major forms of cardiovascular disease were eliminated, life expectancy would rise by close to 7 years.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Anti-platelet therapy stroke risk reduction
    Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.  
  • Increased Use of Medicines Reduces Risk of Death After Major Cardiovascular Events: Disease management program increased use of medicines  
  • TAVR Procedures 2011 – 2015
    From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.